At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed indolent NHL: follicular grade 1-2, small lymphocytic, marginal zone (nodal or splenic), or MALT
- ✓Stage III or IV disease
- ✓Low tumor burden: no nodal/extranodal mass ≥7 cm, <3 nodal masses >3 cm, no B symptoms, splenomegaly ≤16 cm on CT, no vital organ compression risk, no leukemic phase >5000/mm³ lymphocytes, no cytopenias
- ✓At least 1 objective measurable disease parameter (abnormal PET only if verified by CT or other imaging)
- ✕Evidence of transformation to large cell histology
- ✕Prior chemotherapy for lymphoma
- ✕Prior immunotherapy for lymphoma
- ✕Prior radiotherapy for lymphoma
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Phase III Trial Comparing Two Different Rituximab Dosing Regimens For Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
In Brief
A Phase 3 clinical trial evaluating rituximab for Lymphoma. Completed, enrolled 545 participants across 483 sites.
Detailed Summary
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. It is not yet known which rituximab regimen is more effective in treating indolent non-Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying two different schedules of rituximab and comparing them to see how well they work in treating patients with low tumor burden indolent stage III non-Hodgkin's lymphoma or stage IV non-Hodgkin's lymphoma.
Study Details
Timeline
Interventions
Given IV